Compare iShares MSCI Australia ETF (EWA) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs Mesoblast Limited — how do they compare? iShares MSCI Australia ETF trades at $28.64, while Mesoblast Limited trades at $18.69 (market cap $2.31B). Which is the better fit depends on your goals.
| EWA | MESO | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $30.26 | $20.96 |
52-Week Low | $24.95 | $11.35 |
Market Cap | — | $2.31B |
Enterprise Value | — | $2.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWA trades at $28.66, down 0.17% on the day, with a bullish technical signal from moving averages and neutral oscillators. Key support is at $28, while resistance clusters near $29. The stock lacks disclosed financial ratios, and a dividend of $0.40 is scheduled for June 2026. Recent news highlights Australian economic factors and sector-specific developments influencing sentiment.
The outlook is mixed, with technical strength offset by limited fundamental visibility. Risks include reliance on Australian market conditions and macroeconomic headwinds. Investment appeal hinges on future financial disclosures and broader market trends.
Mesoblast (MESO) trades at $19.12, up 14.22% with strong bullish technical signals from moving averages. The biotech company shows promising commercial progress with FDA-approved Ryoncil generating $115M annual revenue, though fundamentals reveal significant losses with a -144.33% net income margin and negative EBITDA of -$80.06M. Recent milestones include achieving Phase 3 trial targets for chronic low back pain and receiving a BLA filing number for heart failure treatment.
Investment outlook balances high growth potential from Mesoblast's cellular medicine platform against substantial financial losses and valuation concerns. The company's transition to commercial operations and pipeline advancements present opportunities, while persistent cash burn and negative profitability represent key risks requiring careful monitoring of upcoming clinical and regulatory catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
